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Aims Circulating microRNAs (miRNAs) have attracted major interest as biomarkers for cardiovascular diseases. Since
RNases are abundant in circulating blood, there needs to be a mechanism protecting miRNAs from degradation.
We hypothesized that microparticles (MP) represent protective transport vehicles for miRNAs and that these are
speciﬁcally packaged by their maternal cells.
Methods
and results
Conventional plasma preparations, such as the ones used for biomarker detection, are shown to contain substantial
numbers of platelet-, leucocyte-, and endothelial cell-derived MP. To analyse the widest spectrum of miRNAs,
Next Generation Sequencing was used to assess miRNA proﬁles of MP and their corresponding stimulated and
non-stimulated cells of origin. THP-1 (monocytic origin) and human umbilical vein endothelial cell (HUVEC) MP
were used for representing circulating MP at a high purity. miRNA proﬁles of MP differed signiﬁcantly from those of
stimulated and non-stimulated maternal THP-1 cells and HUVECs, respectively. Quantitative reverse transcription–
polymerase chain reaction of miRNAs which have been associated with cardiovascular diseases also demonstrated
signiﬁcant differences in miRNA proﬁles between platelets and their MP. Notably, the main fraction of miRNA in
plasma was localized in MP. Furthermore, miRNA proﬁles of MP differed signiﬁcantly between patients with stable
and unstable coronary artery disease.
Conclusion Circulating MP represent transport vehicles for large numbers of speciﬁc miRNAs, which have been associated with
cardiovascular diseases. miRNA proﬁles of MP are signiﬁcantly different from their maternal cells, indicating an active
mechanism of selective ‘packaging’ from cells into MP. These ﬁndings describe an interesting mechanism for transfer-
ring gene-regulatory function from MP-releasing cells to target cells via MP circulating in blood.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Microparticles (MP) are small (,1.1 mm), pro-inﬂammatory vesicles
released by various cell types (e.g. leucocytes, endothelial cells, plate-
lets) in a tightly regulated process. They contain cytoplasm and surface
markers of their cells of origin.
1,2 Once released into the circulation,
MP bind and fuse with their target cells through receptor–ligand
interactions, thereby acting as biological vectors mediating vascular in-
ﬂammation and coagulation.
3,4 Therefore, MP have been shown to
play a pivotal role in several cardiovascular diseases.
5,6 Increasing evi-
dence indicates that inﬂammatory and pro-coagulatory effects of MP
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phosphatidylserine) as well as by the transfer of inﬂammatory cell
components from their cells of origin.
1 However, it was also shown
that MP transport mRNA thereby affecting protein expression of
their target cells.
7 Recent progress in the understanding of microRNA
(miRNA) has prompted the questions of whether MP also affect their
target cells via transferring endogenous miRNAs and whether these MP
have different miRNA patterns than their maternal cells.
miRNAs are a class of small ( 22 nucleotides long), non-coding
RNA that bind to messenger RNAs (mRNAs), thereby acting as en-
dogenous post-translational gene regulators.
8 Since more then 1000
different human miRNAs have already been discovered, the
interaction between miRNAs and mRNAs is highly complex and cur-
rently not completely understood. However, approximately one-third
of human protein-encoding genes are miRNA regulated, underlining
the extraordinary impact of miRNA on protein expression.
9,10
Recent data indicate that miRNAs play a vital role in many cardiovas-
cular diseases and can be found in cardiac tissue as well as in circulat-
ing blood, opening the possibility to use them as diagnostic surrogate
markers.
11–15 Many pioneering studies describing speciﬁc miRNA pat-
terns in cardiovascular diseases used plasma as their source of
miRNAs.
16,17 However, as RNase, which is abundant in circulating
blood, rapidly degrades RNA in plasma, it is a central question how
plasma miRNAs are protected from degradation.
Figure 1 MP derived from stimulated THP-1 cells bind to and fuse with HUVECs. In comparison to non-stimulated THP-1 cells (A), stimulated
THP-1 cells (B) release more MP. Purity and sufﬁcient staining of THP-1 MP were assessed with microscopy (C–E). After 30 min incubation, ﬂuor-
escent MP began to attach on the HUVEC surface and were detectable as distinct ﬂuorescence spots (F–H). Twenty hours after THP-1 MP appli-
cation, HUVECs have internalized the majority of ﬂuorescent MP exhibiting diffuse ﬂuorescence (I–K). Scale bar indicates 10 mm.
P. Diehl et al. 634We used Next Generation Sequencing (NGS) and quantitative
reverse transcription–polymerase chain reaction (qRT–PCR) to sys-
tematically compare miRNA proﬁles of MP with the proﬁles of their
maternal cells in their non-stimulated and stimulated states. Further-
more, we provide evidence for the central role of MP as transfer vehi-
cles of miRNAs in circulation and for the proof of concept that
miRNA proﬁles in circulating MP can be disease-speciﬁc.
2. Methods
2.1 MP attachment to endothelial cells
To show in proof-of-principle experiments that MP attach and fuse with
target cells, such as human umbilical vein endothelial cells (HUVECs), a
static adhesion assay was performed (Figure 1). THP-1 cells were
stained (celltrackerTM, InvitrogenTM, USA) before THP-1 MP release
was induced [lipopolysaccharide (LPS), 15 mg/mL]. MP were isolated
from cell culture supernatant, washed, and added on HUVECs (0.5–
24 h, 378C) before non-adherent MP were removed. Attachment of ﬂuor-
escent THP-1 MP on HUVECs was quantiﬁed microscopically
(Zeiss-Axio-Observer, Germany; ImageJ1.45I, USA).
2.2 Flow cytometry of MP
Investigating whether miRNAs detected in plasma of clinical studies are
associated with MP, the amount of circulating MP was counted with
FACS and MP subpopulations were speciﬁcally labelled. Therefore,
plasma MP were labelled with AnnexinV-APC (InvitrogenTM, USA) and
co-stained with one of the following antibodies: anti-CD41-PE,
anti-CD61-FITC, anti-CD18-FITC (all Beckman Coulter, USA), and
anti-CD62E-FITC (R&D-Systems
w, USA). MP were deﬁned as particles
,1.1 mm (1.1 mm beads, Sigma-Aldrich, Germany) expressing their char-
acteristic surface receptors. All measurements were performed with
FACSCanto (BD Bioscience, USA).
2.3 miRNAs of coronary artery disease patients
To investigate whether blood miRNAs are predominantly associated with
MP, RNA of MP in plasma and plasma without MP of patients with coron-
ary artery disease (CAD) was isolated (Trizol
w, InvitrogenTM, USA) and
qRT–PCR was performed. Plasma of citrate anti-coagulated blood was
prepared, MP were isolated (16 000 g, 90 min), and RNA of MP and
MP-free plasma was isolated before cDNA synthesis was done (Qiagen,
Germany). miRNA proﬁles of circulating MP of patients with stable
CAD (n ¼ 5) were compared with matched patients with acute coronary
syndrome (ACS, n ¼ 5) using qRT–PCR (Table 1). All patients gave their
written informed consent. The study was approved by the local Ethics
Committee.
2.4 Platelet MP preparation and qRT–PCR
Platelet MP were prepared by stimulating platelets from platelet concen-
trates with 20 mM ADP, followed by centrifugation (16 000 g, 2 min) to
separate platelets from platelet MP. The supernatant, which contained
platelet MP, was again centrifuged (16 000 g, 90 min) and RNA was
extracted of the pellet. Purity of MP was controlled with FACS
(Figure 2A). Expression of miRNAs that have been described in plasma
of cardiovascular disease patients or that are known to be expressed
in platelets (miRNA-19, miRNA-21, miRNA-126, miRNA-133,
miRNA-146, miRNA-223, miRNA-451, and miRNA-1246) were analysed
in platelet and platelet MP samples with qRT–PCR (Qiagen). As the ex-
pression of housekeeping genes is often unevenly distributed between
cells and MP, miRNA expression of platelets and platelet MP was
calculated with the quantile-distribution method and is illustrated as
ct values. The study was performed in accordance to the Helsinki
declaration and was approved by the local Ethics Committee
(Alfred-Medical-Research-Centre, Australia).
2.5 THP-1 cell stimulation and MP preparation
THP-1 cells (ATCC, USA) were stimulated with LPS (Fc 15 mg/mL, 24 h)
to obtain stimulated THP-1 cells and THP-1 MP. After stimulation, the
cells were centrifuged (120 g, 20 min) and RNA of the pellet containing
stimulated THP-1 cells was puriﬁed. The corresponding supernatant
was again centrifuged (16 000 g, 90 min) before RNA was extracted
from the pellet which contained MP. To investigate whether MP of stimu-
lated and non-stimulated THP-1 cells have different miRNA proﬁles,
qRT–PCR of several inﬂammatory miRNAs was performed for both
MP types (commercial primers, Qiagen). Furthermore, to investigate
whether stimulated MP induce more endothelial inﬂammation than non-
stimulated MP, HUVECs were incubated with both MP types and vascular
cell adhesion molecule 1 (VCAM-1) and intercellular cell adhesion mol-
ecule 1 (ICAM-1) expression was quantiﬁed by qRT–PCR (commercial
primers, Qiagen and Geneworks, Australia) and FACS (R&D-Systems
w,
Australia, and Chemicon, USA).
2.6 HUVECs stimulation and MP preparation
RNA extraction was done from HUVEC MP as well as from non-
stimulated and stimulated HUVECs. To receive stimulated HUVECs and
HUVEC MP, cells were stimulated with phorbol 12-myristate 13-acetate
(Fc 100 ng/mL, 24 h) and RNA was isolated as described for THP-1.
....................................................................................
Table 1 Clinical characteristics of patients with stable
CAD and ACS
CAD
(n 5 5)
ACS
(n 5 5)
P-value
Age 76+26 6 +4 n.s.
Sex
Male 3 5 n.s.
Female 2 0
Laboratory parameters
Leucocytes (10
3/mL) 6 11 n.s.
Platelets (10
3/mL) 194 158 n.s.
Troponin (ng/mL) 0.05 36 0.04
CK (U/L) 20 901 0.01
Cardiovascular risk factors
Smoking (%) 20 40 n.s.
Hypercholesterolaemia
(%)
40 100 n.s.
Arterial hypertension (%) 100 60 n.s.
Diabetes mellitus (%) 40 40 n.s.
Fam history (%) 20 40 n.s.
Medication
Anti-platelet drugs (%) 80 100 n.s.
ACE/AT1 inhibitors (%) 100 60 n.s.
b-Blocker (%) 20 80 n.s.
Diuretics (%) 60 40 n.s.
Statins (%) 40 80 n.s.
Coronary artery diseases
1-vessel disease 1 —
2-vessel diseases 2 4
3-vessel diseases 2 1
With the exception of cardiac enzymes, baseline characteristics of both groups were
not signiﬁcantly different. n.s., not signiﬁcant.
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In comparison to microarrays or qRT–PCR, NGS has the great advantage
of being able to detect all known miRNAs in the analysed sample and not
only a pool of pre-selected miRNAs. Therefore, to analyse the largest
spectrum of miRNAs, NGS was used for THP-1 cells, HUVECs, and
their MP. One microgram of total RNA was used in a library preparation
according to the Illumina Small RNA Sequencing protocol (v1.5, Illumina,
USA) using Illumina compatible adapters supplied in the AIR Bar-coded
Adapter Set1 (BiooScientiﬁc, USA). Multiplexed libraries were sequenced
at a concentration of 10 pM for 36 cycles. Fastx Toolkit was used
to remove the 3′-adapter sequence, demultiplex, and remove the 6-
mer barcode sequence. A custom script was used to identify all
unique reads (contigs) and generate a counts matrix detailing how
many instances a particular sequence appeared in each bar-coded
sample. Each contig was aligned with BWA against the miRNA-base
hairpin.
18
2.8 Statistics
For qRT–PCR analysis, the housekeeping genes were signiﬁcantly differ-
ent between platelets and platelet MP. Therefore, quantile normalization
was used (Bioconductor, USA) to test whether miRNA was differentially
expressed.
19 Quantile normalization was applied to raw data and analysis
of variance (ANOVA) methods were used to analyse differences in the
expression of each miRNA between both groups. For data analysis of
NGS, read counts were normalized and imported into microarray data
analysis package (Partek
wGenomics SuiteTM, USA). Replicate data was
averaged within the treatment groups and compared with control or ref-
erence groups. ANOVA was used to identify genes that were altered by
more than two-fold. Statistics for categorical variables were performed
with the Fisher exact test (graphpad version 5, USA). Alpha was set in
a two-sided test as 0.05 and data are expressed as mean+SEM.
3. Results
As the aim of the study was to investigate whether MP contain distinct
miRNA patterns compared with their maternal cells, miRNA proﬁles
of the most abundant blood MP (e.g. leucocytes, endothelial cells, plate-
lets) and their corresponding stimulated and non-stimulated parent cells
were analysed. To avoid contamination by other cell types, THP-1 cells
and HUVECs were used as models for monocytes and endothelial cells.
3.1 MP generation and function
as transport vehicle
Highly pure, not contaminated THP-1 MP were obtained from THP-1
cells. To provide evidence for the function as transport vehicles,
Figure 2 Expression of miRNA associated with cardiovascular diseases differs between platelet MP and platelets. (A) Prepared platelet MP (PMP)
samples that were used for RNA isolation were highly pure. (B) Several miRNAs, which are involved in cardiovascular diseases, were detected in PMP.
Interestingly, many miRNAs had different expression levels in MP and platelets suggesting a selective miRNA packaging into PMP. *P , 0.05.
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(.30 min) and fusion (.24 h) to HUVECs (Figure 1), suggesting
that THP-1 MP can function as transport vesicles, therefore repre-
senting a model by which the role of MP in miRNA transport can
be studied.
3.2 Quantiﬁcation of plasma MP
Pioneering clinical studies have found miRNAs in plasma of cardiovas-
cular diseases patients.
16,17 Hypothesizing that these miRNAs are
mainly transported inside MP, we investigated whether plasma con-
tains MP in which miRNAs can be detected. Plasma preparations con-
tained  5200 MP/mL (5200+1340 MP/mL), a number that is in
accordance with previous observations.
20 Forty-one to 45% of circu-
lating MP were of platelet, 28% of leucocyte, and 8% of endothelial
origin. To conﬁrm that MP are the main miRNA compartment in
plasma, qRT–PCRs of different miRNAs were performed analysing
plasma MP compared with MP-free plasma. The predominant
amount of plasma miRNAs was found to be associated with MP
and only small amounts were detected in MP-free plasma, underlining
the importance of MP as miRNA transport vesicles in circulation
(Figure 3A).
3.3 Comparison of miRNAs in patients
with acute vs. stable CAD
To provide proof-of-concept data that differing patterns of
MP-associated miRNAs characterize different diseases, patients with
acute and stable CAD as determined in coronary angiography were
compared with each other (Table 1). Even in a small study population,
patients with stable CAD (n ¼ 5) had signiﬁcantly less MP-associated
pro-inﬂammatory miRNAs than matched patients with ACS (n ¼ 5)
(Figure 3B). These data emphasize the importance of MP as transport
vehicles for inﬂammatory miRNAs in cardiovascular disease patients.
3.4 miRNAs in platelets and their MP
As in many cardiovascular diseases, a co-incidence between increased
platelet MP and circulating miRNAs can be found, we investigated
whether platelet MP contain miRNAs and whether these miRNA pro-
ﬁles differ from that of platelets.
16,21 As shown in Figure 2, miRNA-19,
miRNA-21, miRNA-126, miRNA-133, miRNA-146, miRNA-223,
miRNA-451, and miRNA-1246 were identiﬁed in platelet MP. Inter-
estingly, miRNA-19, miRNA-146, miRNA-223, miRNA-451, and
miRNA-1246 were signiﬁcantly increased in platelet MP, whereas
Figure 3 Circulating miRNAs are mainly associated with MP. The majority of plasma miRNAs are associated with MP and only small amounts can be
found in MP-free plasma of patients with CAD (A). In comparison to patients with stable CAD, larger amounts of different pro-inﬂammatory miRNAs
were found in patients with ACS, underlining the importance of MP-associated miRNAs in patients with acute vs. stable CAD (B). *P , 0.05;
#speciﬁc
miRNA is not detectable.
Distinct miRNA patterns in microparticles 637the expression of miRNA-126 and miRNA-133 were higher in plate-
lets. In summary, platelet MP contain several miRNAs that have been
detected in plasma of patients with cardiovascular diseases. Further-
more, differences in the miRNA proﬁle of platelets and platelet MP
suggest that platelets may have a mechanism to selectively transport
miRNAs into MP.
3.5 NGS of miRNAs in THP-1 cells
and their MP
In all THP-1 samples, a total of 786 different miRNAs were detected.
Forty-four miRNAs signiﬁcantly discriminated between THP-1 MP and
stimulated THP-1 cells (19 miRNAs up-regulated in THP-1 MP vs. 25
miRNAs up-regulated in stimulated THP-1; Figure 4 and Table 2).
Fifty-eight miRNAs were signiﬁcantly different in THP-1 MP in com-
parison to non-stimulated THP-1 cells (23 miRNAs up-regulated in
THP-1 MP vs. 35 miRNAs up-regulated in non-stimulated THP-1)
and 30 miRNAs differed between stimulated and non-stimulated
THP-1 (22 miRNAs up-regulated in non-stimulated THP-1 vs. eight
miRNAs up-regulated in stimulated THP-1). Hence, the miRNA
proﬁle of THP-1 cells changes under stimulation and stimulated
THP-1 cells seem to package a different miRNA pool into MP com-
pared with non-stimulated THP-1 cells.
Figure 4 miRNA proﬁles of stimulated and non-stimulated THP-1 cells as well as THP-1 MP. (A) A heat map diagram shows miRNA clustering of
RNA samples from stimulated and non-stimulated THP-1 cells and THP-1 MP as assessed by NGS. (B) As illustrated in a Venn diagram, miRNA was
not randomly distributed between the groups suggesting the existence of a speciﬁc packaging mechanism of miRNAs into THP-1 MP.
P. Diehl et al. 6383.6 Stimulated THP-1 MP contain
increased inﬂammatory miRNAs
and induce endothelial inﬂammation
Investigating whether MP from stimulated THP-1 cells contain differ-
ent miRNA patterns than those of non-stimulated THP-1 cells, we
found that several pro-inﬂammatory miRNAs are signiﬁcantly
up-regulated in stimulated vs. non-stimulated MP, indicating that the
stimulus inducing MP release can inﬂuence miRNA transport into
MP (Figure 5A). Consecutively, endothelial inﬂammation markers
(VCAM-1 and ICAM-1) were up-regulated after incubation with sti-
mulated THP-1 MP in comparison to non-stimulated THP-1 MP as
determined in qRT–PCR (Figure 5B) and ﬂow cytometry (Figure 5C).
3.7 NGS of miRNAs in HUVECs
and their MP
Analysing miRNA patterns of endothelial cells, a total of 470 different
miRNAs were detected in HUVEC samples. Fifty-nine miRNAs signiﬁ-
cantly discriminated between stimulated and non-stimulated HUVECs
(53 miRNAs up-regulated in stimulated HUVECs vs. six miRNAs
up-regulated in non-stimulated HUVECs) (Figure 6 and Table 3). Sixty-
six miRNAs were signiﬁcantly different in HUVEC MP in comparison
to stimulated cells (11 miRNAs up-regulated in HUVEC MP vs. 55
miRNAs up-regulated in stimulated HUVECs) and 36 miRNAs dif-
fered between HUVEC MP and non-stimulated HUVECs (18
miRNAs up-regulated in HUVEC MP vs. 18 miRNAs up-regulated in
non-stimulated HUVECs). These data demonstrate that stimulated
endothelial cells possess signiﬁcantly different miRNA patterns com-
pared with the non-stimulated endothelium. Furthermore, HUVECs
seem to selectively pack their MP with distinct miRNAs.
4. Discussion
To investigate whether MP contain speciﬁc miRNAs delivered from
their maternal cells, NGS of THP-1 cells and HUVECs as well as
qRT–PCR of platelet MP and of their corresponding maternal cells
were performed. NGS is a promising method for miRNA studies as
it has major advantages in comparison to microarrays, including
higher sensitivity, wider miRNA spectrum that can be analysed and
the ability of de novo sequencing of so far unknown miRNAs.
22,23
We could demonstrate that MP contain a signiﬁcantly distinct
miRNA pattern compared with their corresponding stimulated and
non-stimulated maternal cells, suggesting a selective miRNA transport
into MP. Several of the miRNAs up-regulated in MP are involved in
cardiovascular diseases, indicating that MP may act as transport vehi-
cles delivering speciﬁc miRNAs (Table 4). Since MP are major consti-
tuents of typical plasma preparations, ‘plasma’ miRNA proﬁles
attributed to speciﬁc diseases may in fact originate from circulating
MP. Our ﬁndings, which show that plasma deprived of MP demon-
strates a signiﬁcant reduction in miRNAs, support this notion.
MP represent a novel mechanism of intercellular communication
mediating inﬂammation and coagulation.
24,25 Their effect on target
cells was long accredited to their speciﬁc lipid composition, as well
as to intravesicular chemokines.
1 However, recent data indicate that
MP can also affect protein expression of their target cells by delivering
RNAs.
7,26 As it is evident that MP shedding is a highly structured
process, the question arises whether miRNAs are speciﬁcally
packed from maternal cells into MP, thereby protecting their
miRNAs from degradation by plasma RNase.
27,28 In a pioneering
study by Hunter et al.,
29 it was found that blood MP contain some
miRNAs that may be released from peripheral blood mononuclear
cells. However, as the mixture of MP circulating in blood may origin-
ate from different cell types, no conclusion could be drawn on
whether the proﬁle of miRNAs in MP reﬂect the proﬁle seen in
their maternal cells.
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Table 2 Differences in miRNA abundance of THP-1 MP in
comparison to stimulated THP-1 cells
miRNA Fold change P-value
miRNA-1290 230  0.045
miRNA-4284 191  0.043
miRNA-1246 54  0.006
miRNA-486 11  0.005
miRNA-642b 11  0.039
miRNA-1973 10  0.013
miRNA-130a 7  0.022
miRNA-3929 6  0.018
miRNA-320 6  0.028
miRNA-139 5  0.016
miRNA-548k 5  0.008
miRNA-566 5  ,0.001
miRNA-619 5  0.016
miRNA-3648 5  0.021
miRNA-423 3  0.021
miRNA-500b 3  0.046
miRNA-3184 3  0.047
miRNA-1273 3  ,0.001
miRNA-2277 2  0.022
miRNA-1255a 228  0.039
miRNA-450a-1 214  0.030
miRNA-1224 212  0.001
miRNA-143 28  0.011
miRNA-1–2 27  0.008
miRNA-340 26  0.011
miRNA-212 25  ,0.001
miRNA-132 25  0.026
miRNA-15b 24  0.008
miRNA-9-3 24  0.005
miRNA-301b 24  0.011
miRNA-550b-2 24  0.015
miRNA-455 24  ,0.001
miRNA-374a 24  0.007
miRNA-147b 23  0.041
miRNA-20a 23  0.006
miRNA-1260b 23  0.029
miRNA-570 23  0.030
miRNA-484 23  0.010
miRNA-548aa-1 23  0.018
miRNA-21 23  0.042
miRNA-218-1 23  0.041
miRNA-362 23  0.003
miRNA-450b 22  0.029
miRNA-27a 22  ,0.001
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majority of plasma miRNAs are associated with MP, both in patients
with stable CAD as well as with ACS and that only a small amount
of miRNA is located in MP-free plasma, underlining the importance
of MP as biological vectors for miRNAs (Figure 3A). Interestingly,
several miRNAs that were detected in ‘plasma’ of clinical studies
were also found in plasma MP (Figure 3). In addition, ACS patients
had signiﬁcantly higher levels of some MP-associated
pro-inﬂammatory miRNAs than stable CAD patients. Some of these
plasma miRNAs were also found to be signiﬁcantly up-regulated in
isolated platelet MP, whereas others were higher expressed in plate-
lets, indicating a speciﬁc miRNA transport into platelet MP (Figure 2).
Recent data indicate that miRNA-133, which was found in platelet MP,
is involved in different cardiovascular diseases, such as myocardial in-
farction.
30 Villar et al.
31 demonstrated elegantly that miRNA-133 func-
tions as a surrogate marker for reverse remodelling in cardiac
hypertrophy, a disease that is strongly inﬂuenced by activated plate-
lets.
32 Moreover, miRNA-133 was found to be increased in plasma
Figure 5 MP from stimulated THP-1 cells contain increased pro-inﬂammatory miRNA than from non-stimulated THP-1 cells and induce more vas-
cular inﬂammation. (A) MP released from stimulated THP-1 cells have higher expression levels of several inﬂammatory miRNAs than those from non-
stimulated THP-1 cells. Consecutively, they induce more endothelial inﬂammation as quantiﬁed by qRT–PCR (B) and ﬂow cytometry (C) than MP
from non-stimulated THP-1 cells. *P , 0.05.
P. Diehl et al. 640of patients with myocardial infarction, who are also known to have
elevated levels of circulating MP.
33 Also, miRNA-19, which has been
shown to be involved in cardiac hypertrophy and angiogenesis, was
signiﬁcantly up-regulated in platelet MP (Figure 2).
34,35 In conclusion,
MP contain the majority of plasma miRNAs. Furthermore, platelet
MP have a different miRNA pattern than platelets themselves and
contain several miRNAs that were found in plasma of cardiovascular
diseases.
To our knowledge, this is the ﬁrst study showing that THP-1 MP
contain a signiﬁcantly distinct miRNA proﬁle compared with their sti-
mulated and non-stimulated maternal cells (Figure 4). Nineteen
miRNAs were found to be signiﬁcantly increased in THP-1 MP in
comparison to stimulated THP-1 cells, and 58 miRNAs discriminated
THP-1 MP from their non-stimulated cells of origin. miRNA-130a,
miRNA-320, and miRNA-423 were signiﬁcantly up-regulated in
THP-1 MP. Chen et al.
36 found that miRNA-130a has strong
pro-angiogenetic properties by down-regulation of GAX, an anti-
angiogenic homeobox gene. This pro-angiogenic effect of
miRNA-130a might be the underlying molecular mechanism for the
observation that MP of plaque macrophages induce in vivo intra-plaque
neovessel formation, therefore contributing to plaque instability.
37
miRNA-320 is known to play a pivotal role in ischaemic reperfusion
Figure 6 miRNA proﬁles of stimulated and non-stimulated HUVECs as well as HUVEC MP. (A) As illustrated in a heat map diagram, multiple
miRNAs were differentially expressed in HUVEC MP and HUVECs. (B) As illustrated in a Venn diagram, miRNAs were not randomly distributed
between the groups suggesting the existence of a speciﬁc packaging mechanism of miRNAs into HUVEC MP.
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38,39 a disease that is associated with enhanced monocytotic
MP, suggesting that THP-1 MP directly inﬂuence pro-inﬂammatory
gene expression in cardiac tissue by transferring miRNAs, such as
miRNA-320. Tijsen et al.
40 investigated miRNA in serum of patients
with cardiac failure and detected six miRNAs that were signiﬁcantly
increased in comparison to controls. Among these, miRNA-423,
which was found to be signiﬁcantly increased in THP-1 MP, correlated
most strongly with the clinical diagnosis of cardiac failure. Recent evi-
dence is suggestive of miRNA-423 being used as a marker for cardiac
failure.
41 As it is known that the stimulus inducing MP release inﬂu-
ences miRNA packaging from the corresponding maternal cell, ex-
pression levels of inﬂammatory miRNA were assessed in stimulated
and non-stimulated THP-1 MP (Figure 5). Interestingly, many
pro-inﬂammatory miRNAs were signiﬁcantly increased in stimulated
THP-1 MP (Figure 5A). miRNA-21 is one of the highest up-regulated
miRNAs in stimulated vs. non-stimulated THP-MP and is described
to be up-regulated under hypoxic conditions in vascular smooth
muscle cells inducing endothelial inﬂammation (e.g. VCAM-1 expres-
sion) and to play a pivotal role in the transition of endothelial cells to
ﬁbroblasts during inﬂammation.
42–44 Consecutively, stimulated THP-1
MP had a stronger inﬂammatory effect on HUVECs when compared
with MP of non-stimulated THP-1 cells, both on the mRNA level as
well as on surface receptor expression (Figure 5B and C).
Intact endothelial cells are essential for maintenance of vascular in-
tegrity and haemostasis. However, stimulated endothelium releases
endothelial MP, which, besides functioning as surrogate markers for
early endothelial dysfunction, are biological vectors mediating vascular
inﬂammation and coagulation at a distant site from the initially
damaged endothelial cells.
24 Aiming to investigate whether biological
effects of endothelial MP may also be attributed to miRNA transfer,
miRNA patterns of HUVECs and HUVEC MP were investigated.
We found that HUVEC MP had a signiﬁcantly different miRNA
proﬁle than stimulated and non-stimulated HUVECs (Figure 6). Sixty-
six miRNAs were differently expressed between HUVEC MP and
their stimulated maternal cells, from which 11 were up-regulated in
HUVEC MP. Among the up-regulated miRNAs in HUVEC MP were
miRNA-451 and miRNA-486. miRNA-486 is a cardiac enriched,
....................................................................................
Table 3 Differences in miRNA abundance of HUVEC MP
in comparison to stimulated HUVECs
miRNA Fold change P-value
miRNA-451 124  0.006
miRNA-1908 15  ,0.001
miRNA-4284 14  0.002
miRNA-1246 12  0.02
miRNA-3168 12  0.018
miRNA-1290 11  0.011
miRNA-3195 10  0.011
miRNA-659 9  0.035
miRNA-1273e 6  0.026
miRNA-3665 5  0.001
miRNA-486 3  0.014
miRNA-15a 13  0.012
miRNA-30e 12  0.022
miRNA-299 10  0.004
miRNA-15b 9  0.027
miRNA-378 8  0.036
miRNA-454 8  0.049
miRNA-195 7  0.039
miRNA-181a-1 7  0.005
miRNA-16-1 7  0.011
miRNA-16-2 7  0.002
miRNA-181c 7  0.004
miRNA-330 7  0.019
miRNA-10b 7  ,0.001
miRNA-656 6  0.007
miRNA-539 6  0.049
miRNA-20a 6  0.008
miRNA-584 5  0.025
miRNA-181a-2 5  0.047
miRNA-140 5  0.048
miRNA-668 5  ,0.001
miRNA-889 5  0.01
miRNA-625 5  ,0.001
miRNA-1226 5  0.009
miRNA-425 5  0.008
miRNA-655 5  0.03
miRNA-362 4  ,0.001
miRNA-340 4  0.011
miRNA-455 4  0.019
miRNA-34a 4  0.04
miRNA-21 4  0.021
miRNA-502 4  0.04
miRNA-10a 4  0.029
miRNA-500b 4  0.025
miRNA-125a 3  0.031
miRNA-497 3  0.004
miRNA-374c 3  0.033
miRNA-103-2-as 3  0.002
miRNA-151 3  0.016
miRNA-24-2 3  0.037
miRNA-365-2 3  ,0.001
miRNA-1285-2 3  0.01
Continued
....................................................................................
Table 3 Continued
miRNA Fold change P-value
miRNA-146a 3  0.003
miRNA-186 3  0.012
miRNA-181b-2 3  ,0.001
miRNA-3074 3  0.018
miRNA-146b 3  0.042
miRNA-222 3  ,0.001
miRNA-23b 3  0.023
miRNA-331 3  0.003
miRNA-720 3  0.038
miRNA-342 2  0.039
miRNA-23a 2  0.048
miRNA-24-1 2  0.032
miRNA-199a-1 2  0.021
miRNA-30c-2 2  0.004
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up-regulated in HUVEC and THP-1 MP in comparison to their stimu-
lated maternal cells (Tables 2 and 3). Our ﬁndings are supported by a
study of Hunter et al.,
29 who found miRNA-486 to be the highest dif-
ferentially expressed miRNA in plasma microvesicles compared with
peripheral blood monocytic cells. miRNA-451 was signiﬁcantly
up-regulated in HUVEC MP and strongly inhibits expression of macro-
phage migration factor (MIF), a pluripotent pro-inﬂammatory cardiac
depressant.
45 Garner et al. showed that MIF impaired left ventricular
function, an effect that was reversible after anti-MIF antibody treat-
ment.
46 Overall, this indicates that miRNA-451 may possess cardio-
protective effects by inhibiting MIF, which might be an attractive
therapeutic approach warranting interesting future studies.
In conclusion, using NGS, we could show that THP-1, HUVEC, and
platelet MP contain numerous miRNAs, which signiﬁcantly differ from
their maternal cells, both in stimulated and non-stimulated states.
These data indicate a speciﬁc ‘packaging’ or delivery mechanism of
miRNAs from maternal cells into MP, a topic which warrants
further studies. Most interestingly, for the use of miRNAs as biomar-
kers, miRNAs detected in conventional plasma preparations seem to
be localized mainly in MP.
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